Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

Completed · Phase 2 · Has a placebo group

Conditions studied: Influenza

In brief

This Phase 2 protocol is designed to compare two dose levels of laninamivir octanoate versus placebo. The objectives are to obtain safety and efficacy in adults aged 18 to 64 years who present to clinic with symptomatic presumptive influenza A or B infection.

Key facts

Study ID
NCT01793883
Run by
Biota Scientific Management Pty Ltd
People needed
639
Starts
2013-05-01
Expected to finish
2014-05-01
Last updated by the study team
2018-05-31

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.